Rosacea associated with dupilumab therapy
Background: Dupilumab is used for treatment of atopic dermatitis through blockade of IL-4 and IL-13 signaling of the Th2 pathway. Recent case reports have described alopecia, psoriasis, persistent facial dermatitis, and recall dermatitis at patch test sites after the initiation of dupilumab therapy....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2019.1624683 |
| _version_ | 1797683661617758208 |
|---|---|
| author | Haley D. Heibel Aleksi J. Hendricks James P. Foshee Vivian Y. Shi |
| author_facet | Haley D. Heibel Aleksi J. Hendricks James P. Foshee Vivian Y. Shi |
| author_sort | Haley D. Heibel |
| collection | DOAJ |
| description | Background: Dupilumab is used for treatment of atopic dermatitis through blockade of IL-4 and IL-13 signaling of the Th2 pathway. Recent case reports have described alopecia, psoriasis, persistent facial dermatitis, and recall dermatitis at patch test sites after the initiation of dupilumab therapy. Case report: We describe the case of a 67-year-old female with atopic dermatitis who developed recurrent episodic flares of rosacea temporally associated with dupilumab injections that resolved after dupilumab discontinuation. Conclusion: The cause of rosacea-like reaction associated with dupilumab treatment is unknown. Th2 pathway inhibition by dupilumab may promote Demodex proliferation and increased IL-17-mediated inflammation implicated in the pathophysiology of rosacea. Abbreviations: atopic dermatitis: AD; interleukin: IL; persistent facial dermatitis: PFD; T-helper cell type 1: Th1; T-helper cell type 2: Th2; T-helper cell type 17: Th17; tumor necrosis factor-∝: TNF-∝ |
| first_indexed | 2024-03-12T00:18:05Z |
| format | Article |
| id | doaj.art-5b0ad12854b44d069e915f7c5792b6cb |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:18:05Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-5b0ad12854b44d069e915f7c5792b6cb2023-09-15T14:23:02ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532021-01-0132111411610.1080/09546634.2019.16246831624683Rosacea associated with dupilumab therapyHaley D. Heibel0Aleksi J. Hendricks1James P. Foshee2Vivian Y. Shi3Creighton UniversityUniversity of ArizonaUniversity of ArizonaUniversity of ArizonaBackground: Dupilumab is used for treatment of atopic dermatitis through blockade of IL-4 and IL-13 signaling of the Th2 pathway. Recent case reports have described alopecia, psoriasis, persistent facial dermatitis, and recall dermatitis at patch test sites after the initiation of dupilumab therapy. Case report: We describe the case of a 67-year-old female with atopic dermatitis who developed recurrent episodic flares of rosacea temporally associated with dupilumab injections that resolved after dupilumab discontinuation. Conclusion: The cause of rosacea-like reaction associated with dupilumab treatment is unknown. Th2 pathway inhibition by dupilumab may promote Demodex proliferation and increased IL-17-mediated inflammation implicated in the pathophysiology of rosacea. Abbreviations: atopic dermatitis: AD; interleukin: IL; persistent facial dermatitis: PFD; T-helper cell type 1: Th1; T-helper cell type 2: Th2; T-helper cell type 17: Th17; tumor necrosis factor-∝: TNF-∝http://dx.doi.org/10.1080/09546634.2019.1624683dupilumabatopic dermatitisrosacea |
| spellingShingle | Haley D. Heibel Aleksi J. Hendricks James P. Foshee Vivian Y. Shi Rosacea associated with dupilumab therapy Journal of Dermatological Treatment dupilumab atopic dermatitis rosacea |
| title | Rosacea associated with dupilumab therapy |
| title_full | Rosacea associated with dupilumab therapy |
| title_fullStr | Rosacea associated with dupilumab therapy |
| title_full_unstemmed | Rosacea associated with dupilumab therapy |
| title_short | Rosacea associated with dupilumab therapy |
| title_sort | rosacea associated with dupilumab therapy |
| topic | dupilumab atopic dermatitis rosacea |
| url | http://dx.doi.org/10.1080/09546634.2019.1624683 |
| work_keys_str_mv | AT haleydheibel rosaceaassociatedwithdupilumabtherapy AT aleksijhendricks rosaceaassociatedwithdupilumabtherapy AT jamespfoshee rosaceaassociatedwithdupilumabtherapy AT vivianyshi rosaceaassociatedwithdupilumabtherapy |